According to Global Cord Blood's latest financial reports the company has $1.04 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2022-03-31 | $1.04 B | 13.51% |
2021-03-31 | $0.92 B | 19.93% |
2020-03-31 | $0.77 B | 3.53% |
2019-03-31 | $0.74 B | 10.07% |
2018-03-31 | $0.67 B | 32.79% |
2017-03-31 | $0.50 B | 9.33% |
2016-03-31 | $0.46 B | 18.15% |
2015-03-31 | $0.39 B | 29.94% |
2014-03-31 | $0.30 B | 26.3% |
2013-03-31 | $0.24 B | 90.41% |
2012-03-31 | $0.12 B | 35.21% |
2011-03-31 | $93.36 M | 126.59% |
2010-03-31 | $41.2 M | |
2008-12-31 | $28.9 M | 5856.86% |
2007-12-31 | $0.48 M | -47.21% |
2006-12-31 | $0.91 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
RadNet RDNT | $0.34 B | -67.36% | ๐บ๐ธ USA |
National Healthcare
NHC | $0.22 B | -78.69% | ๐บ๐ธ USA |
NeoGenomics
NEO | $0.41 B | -60.44% | ๐บ๐ธ USA |
Cryo-Cell CCEL | $0.98 M | -99.91% | ๐บ๐ธ USA |